Search results
EU gives green light to new drug from pharma giant GSK to treat endometrial cancer
Euronews via Yahoo News· 5 months agoBritish pharmaceutical company GlaxoSmithKline (GSK) announced on Monday that it has received...
Shingles Vaccine Market is Booming in Near Future 2023-2031
NewMediaWire via Yahoo Finance· 1 year agoPune, India - (NewMediaWire) - March 3, 2023 - "Shingles Vaccine" Size, Scope, and Forecast...
1 Stock Down 43% to Buy and Hold for 10 Years
Motley Fool via Yahoo Finance· 4 months agoThe pandemic has receded substantially, and with it, the need for vaccines and medicines against COVID-19. That's not to say we no longer need them --...
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK
Reuters via Yahoo Finance· 1 year agoThe Biden Administration told the U.S. Supreme Court on Wednesday that it should agree to hear a...
US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
Reuters via Yahoo News· 12 months agoThe U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235...
The Zacks Analyst Blog Highlights Caterpillar, Equinor, GSK, Sysco and AmerisourceBergen
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – January 9, 2023 – Zacks.com announces the list of stocks...
These Companies Paid Massive Sums to Settle Lawsuits
Cheapism via AOL· 1 year agojetcityimage/istockphoto Big Business Fails Corporations may enjoy many of the same rights as citizens under U.S. law, but they certainly aren't punished...
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool· 2 years agoEarlier this month, Merck (NYSE: MRK) announced that in a phase 3 clinical trial its drug candidate,...
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
Zacks via Yahoo Finance· 2 years agoGilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic...
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
Zacks via Yahoo Finance· 2 years agoVIR shares gain following a multi-year contract from BARDA for the development of influenza and...
